Prostate Cancer Therapeutics - Global Strategic Business Report

  • ID: 992765
  • Report
  • Region: Global
  • 339 Pages
  • Global Industry Analysts, Inc
1 of 4

FEATURED COMPANIES

  • AbbVie, Inc. (USA)
  • Allergan plc (Ireland)
  • Amgen, Inc. (USA)
  • AstraZeneca Plc. (UK)
  • Bayer AG (Germany)
  • Genentech Inc. (USA)
  • MORE

The report provides separate comprehensive analytics for the US, Canada, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Prostate Cancer Therapeutics in US$ Million by the following Segments:

  • Hormone Therapy
  • Other Therapies.

Company profiles are primarily based on public domain information including company URLs. The report profiles 76 companies including many key and niche players such as:

  • AbbVie, Inc.
  • Allergan plc
  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca Plc
  • Bayer AG
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie, Inc. (USA)
  • Allergan plc (Ireland)
  • Amgen, Inc. (USA)
  • AstraZeneca Plc. (UK)
  • Bayer AG (Germany)
  • Genentech Inc. (USA)
  • MORE

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Hormone Therapy
Other Therapies
Radiation Therapy
Immunotherapy
Chemotherapy

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW
An Insight in the Global Market for Prostate Cancer Diagnostics and Therapeutics
Rising Incidence of Prostate Cancer: Cornerstone for the Market
Table 1: Global Cancer Incidence (2015): Number of New Cancer Cases in Thousands by Type and Gender (includes corresponding Graph/Chart)
Table 2: Global Cancer Mortality (2015): Number of Cancer Related Deaths in Thousands by Type and Gender (includes corresponding Graph/Chart)
Table 3: Prostate Cancer Incidence Worldwide: Comparative Analysis for the Years 2004, 2007, 2012 and 2015 (includes corresponding Graph/Chart)
Current & Future Analysis
Developed Markets: Traditional Revenue Contributors
Table 4: Healthcare Spending as a Percentage of GDP by Region (2016) (includes corresponding Graph/Chart)
Developing Countries Turbo Charge Future Market Growth
An Insight into the Castration-Resistant Prostate Cancer Therapeutics Market
Market Outlook & Trends
Zytiga (Abiraterone acetate): The Market Leader
Table 5: Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2017 (includes corresponding Graph/Chart)
Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC)
Hormone Therapies to Dominate Global Prostate Cancer Therapeutics Market
Key Prostate Cancer Hormone Therapy Drugs & Companies: 2017
Targeted Therapy
The New Frontier of Cancer Treatment
Radiotherapy
Gaining Prominence
Metastatic Prostate Cancer
Apt for Precision Oncology
Launch of Generic Drugs to Place Established Players in Jeopardy
Demographics & Lifestyles Raise the Risk of Prostate Cancer
Table 6: Probability of Developing Invasive Prostate Cancer by Age Group in the US: 2012-2014 (includes corresponding Graph/Chart)
Select General Risk Factors and their Relative Risk Rate in Prostate Cancer
Small Cap Companies: A Target of Private Capital Financing
Cost Analysis of Currently Available Treatment
Table 7: Prices of Xtandi by Country (2016): Prices of Xtandi 40 mg Capsule/Tabs in the US and Other High-Income Countries (includes corresponding Graph/Chart)
Growth Drivers
Rise in Prostate Cancer Incidence & Access to Modern Therapeutics Foster Growth
Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
Table 8: Five-Year Prostate Cancer Survival Rate (%) Among US Males (2007-2013)
Awareness Drives European Prostate Cancer Therapeutics Market
Minimally Invasive Devices to Gain Share in Emerging Markets
Supportive Cancer Drugs Contribute to Growth
Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer
Developments in Proteomics Favor Market
Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
Growth Restraints
Costly & Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
Limited Tumor Specificity and Toxicity
Multiple Drug Resistance
Stringent Regulations Delay Market Approval
Challenges Faced by Patients and Clinicians in Diagnosis and Treatment
Challenges Encountered in Clinical Trials
Select Recent Prostate Cancer Drug Trial Failures
High Development Costs Retracts Manufacturers in Developing Countries
Pipeline of Drugs in Clinical Trials
New Products to Bolster Sales of Prostate Cancer Therapeutics
Select Prostate Cancer Drugs in the Pipeline (2018)
Marine Sponge-Derived Compound Shows Promise against Prostate Cancer
New Combination Treatment for Advanced mCRPC
Risk of Alzheimer’s dampens the Market
Innovations & Advancements
Research and Development Findings
Additional Tests to be used with PSA for Better Diagnosis of Prostate Cancer
New Approaches in Diagnosis and Staging of Prostate Cancer
New Developments in Treatment Methods and Diet Strategies
Innovative mCRPC Treatment Options to Enhance Quality of Life
New Drug Class (sphingolipid pathway inhibitor) Shows Potential for Slowing down Growth
Neural Stem Cell Therapy: Revolutionary Step to Combat Cancer
Ailanthone Identified as Potential Therapeutic for the Treatment of CRPC
Laser Activated Treatment for Prostate Cancer Developed
Photodynamic Therapy Offers Potential to Treat Prostate Cancer
Combination of Therapies under Research
Future Research Strategies to Benefit from Open Access Publishing
Innovations in Drug Delivery: A Key Factor in Product Differentiation

2. PRODUCT OVERVIEW
Cancer: A Major Health Crisis in the Modern World
Prostate
Structure
Pituitary Gland
Testes
Prostate Cancer
A Primer
Key Facts
Table 9: Lifetime Probability of Developing Prostate Cancer by Age in % and Odds
2010-2015 (includes corresponding Graph/Chart)
Table 10: Prostate Cancer Incidence and Mortality Rate in the World by Region: 2015 (includes corresponding Graph/Chart)
Screening/Detection of Prostate Cancer
Digital Rectal Exam (DRE)
Transrectal Ultrasound (TRUS)
PSA Blood Test
Strategies to Enhance Screening/Detection of Prostate Cancer
Improved PSA Testing
Total PSA, Free PSA and PSA-Alpha-1-Protease Inhibitor Levels
Insulin-like Growth Factor (IGF-1) and Intact IGF-Binding Protien-3 (IGF-BP3)
GSTP1 Methylation Levels and Prostate Cancer Diagnosis
Microbubble Ultrasound
Staging of Prostate Cancer
Gleason Score
Gleason Score and Grading of Prostate Cancer
TNM Staging
T-Staging Analysis of Prostate Cancer
Genetic & Non-Genetic Factors
Hereditary or Genetic Factors
Non-Genetic or Environmental Factors
Table 11: Prostate Cancer Incidence/Mortality Rate in the US by Ethnicity (2010-2014) (includes corresponding Graph/Chart)
Prevention of Cancer
Role of Diet in Prostate Cancer
Treatment Options for Prostate Cancer
Hormonal Therapy
Medical Hormone Therapy
LHRH Analogs
Dose of LHRH Agonists for Advance Prostate Carcinoma Treatment
Anti-Androgens
Anti-Androgen Monotherapy
Orchiectomy
Side Effects of Orchiectomy
Time to Start Hormonal Therapy
Strategies to Enhance Hormonal Treatment
Combination Therapy
Intermittent Therapy
Radiation Therapy
Brachytherapy
Table 12: Brachytherapy Market by Application Area (2017): Percentage Share Breakdown for Breast, Gynecology, Prostate and Others (includes corresponding Graph/Chart)
Treatment Procedure
Benefits of Brachytherapy
Drawbacks of Brachytherapy
High Dose Rate (HDR) Brachytherapy
External Beam Radiation Therapy (EBRT)
Side Effects of Radiotherapy
Strategies to Enhance Radiation Treatment
Chemotherapy
Risks Associated with Chemotherapy
Surgical Procedures for Prostate Cancer
Transurethral Resection of the Prostate (TURP)
Prostatectomy and Lymph Node Dissection
Radical Prostatectomy
Cryosurgery
Advantages of Cryosurgery:
Disadvantages of Cryosurgery:
Other Treatment Options
Intensity Modulated Radiation Therapy (IMRT)
Benefits of IMRT
Drawbacks of IMRT
Androgen Deprivation Therapy (ADT)
High Dose Radiation (HDR) Monotherapy
Drawbacks of HRD
Choosing the Optimal Treatment Method
Recurrent Prostate Cancer
Recurrent Prostate Cancer Subsequent to Surgery
Recurrent Prostate Cancer Subsequent to Radiation Therapy
Hormone-Refractory Prostate Cancer (HRPC)
Select Drugs for Hormone-Refractory Prostate Cancer
Chemotherapy
Taxotere® (Docetaxel)
Bone Complication Treatments
Bisphosphonate Drugs
Radiation Therapy
Strategies to Enhance Recurrent Prostate Cancer Treatment
Chemotherapy
New Regimens
Phase I Clinical Trials
Combination Therapy
Gene Therapy
Targeted Therapy
Selective Endothelia A Receptor Antagonist
(SERA™)
Other Select Targeted Therapies
Tyrosine Kinase Inhibitors
Anti-Angiogenic Drugs
Monoclonal Antibodies
Vaccines
Radioactive Monoclonal Antibodies
Distribution Channels

3. DRUG APPROVALS AND CLINICAL STUDIES
Janssen Biotech Receives Approval for Erleada
Janssen Pharmaceutical Bags Approval for ZYTIGA® for Metastatic High-Risk CSPC
Janssen Biotech Submits Supplemental NDA for ZYTIGA® to Treat Early Stage Metastatic Prostate Cancer
Bavarian Nordic to Discontinue Phase 3 PROSPECT Study on mCRPC
Bavarian Nordic Announces Phase 2 Clinical Trial of PROSTVAC
OncBioMune Pharmaceuticals Offers Latest Clinical Data of ProscaVax
Pfizer and Astellas Pharma Announces Phase 3 PROSPER Trial Results of XTANDI®
EMA Issues Positive Opinion to Include Data in European Label for XTANDI
Cofepris Approves Weizmann Institute Drug TOOKAD® Soluble
OncBioMune Pharmaceuticals Reports Positive Phase 1 Results of ProscaVax
FDA Accepts Xtandi sNDA by Astellas Pharma for Review
Progenics Pharmaceuticals Begins Phase 3 Clinical Trial Enrollment for 1404
FDA Grants Astrazeneca’s Lynparza™ Breakthrough Therapy Designation
Nanobiotix’s Investigational New Drug NBTXR3 Set for First Clinical Trial
Minomic International to Launch Human Trial of Its MAb Technology
Takeda Receives NDA Approval for Leuplin
Progenics Enters into Licensing Agreement with Johns Hopkins for Clinical-Stage PSMA Agent
ZYTIGA Receives FDA Approval for Label Update
Valeant Reports Long-Term results of Phase II STAND Trial of PROVENGE
OncoGeneX Pharmaceuticals to Regain Rights on Experimental Drug Custirsen from Teva

4. PRODUCT LAUNCHES
QIAGEN Commercializes AdnaTest Prostate Cancer Panel AR-V7 for Research Use
GenomeDx Biosciences Launches Decipher Biopsy Test for Prostate Cancer
Profound Medical and Siemens Sign Agreement to Launch TULSA- PROTM System
Aeterna Zentaris Begins Promotional Activities for APIFINY® Test
Biocept Launches Androgen Receptor Expression Assay for Prostate Cancer Detection
Augmenix Reports Robust Commercial Uptake of SpaceOAR® System during Radiotherapy
MDxHealth SA Launches SelectMDx Test in Europe
Bayer Launches Xofigo in Ontario

5. RECENT INDUSTRY ACTIVITY
Valeant Pharmaceuticals International to Divest Dendreon Pharmaceuticals to Sanpower Group
AbbVie Enters into Immuno-Oncology Research Collaboration with Harpoon Therapeutics
AstraZeneca Inks Pact with TerSera Therapeutics
Bristol-Myers Squibb and Clovis Oncology Ink a Broad Clinical Collaboration Agreement
J&J Expands Market for Zytiga
Telix Pharmaceuticals Completes Product Collaboration and Purchase Option Agreement with Atlab Pharma
UCLA Sells Xtandi Rights to Royalty Pharma
Aytu BioScience Enters into Study Agreement with Hybridyne Imaging Technologies
Crown Bioscience Signs Licensing Agreement with University of York for PDX Models
Hologic Acquires DiagnoCure’s Prostate Cancer Biomarker Assets
Aeterna Zentaris Enters into Co-Marketing Agreement with Armune
Exiqon Acquires Licensing Rights on Prostate Cancer Biomarkers from University Hospital
Mylan Sued for ANDA for Generic Version of Zytiga
Aytu BioScience Acquires Jazz Pharmaceuticals’ rights to ProstaScint
OPKO Health to Acquire Bio-Reference Laboratories
Boston Scientific to Acquire American Medical Systems’ Urology Portfolio
Valeant to Acquire Dendreon’s Assets

6. FOCUS ON SELECT GLOBAL PLAYERS
AbbVie, Inc. (USA)
Allergan plc (Ireland)
Amgen, Inc. (USA)
Astellas Pharma, Inc. (Japan)
AstraZeneca Plc. (UK)
Bayer AG (Germany)
Bristol-Myers Squibb Company (USA)
Debiopharm Group (Switzerland)
Dendreon Pharmaceuticals LLC (USA)
Endo Pharmaceuticals Inc. (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Genentech Inc. (USA)
GlaxoSmithKline Plc. (UK)
Janssen Biotech, Inc. (USA)
Myovant Sciences Ltd. (UK)
Novartis AG (Switzerland)
Pfizer, Inc. (USA)
Progenics Pharmaceuticals, Inc. (USA)
Sanofi S.A. (France)
Spectrum Pharmaceuticals, Inc. (USA)
Takeda Pharmaceutical Company Limited (Japan)
TOLMAR Pharmaceuticals, Inc. (USA)

7. GLOBAL MARKET PERSPECTIVE
Table 13: World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region/Country
US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 14: World Historic Review for Prostate Cancer Therapeutics by Geographic Region/Country
US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 15: World 14-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country
Percentage Breakdown of Dollar Sales for US, Canada, Europe, and Rest of World Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)
Segmental Analytics
Table 16: World Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region/Country
US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 17: World Historic Review for Hormone Therapy by Geographic Region/Country
US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 18: World 14-Year Perspective for Hormone Therapy by Geographic Region/Country
Percentage Breakdown of Dollar Sales for US, Canada, Europe, and Rest of World Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)
Table 19: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region/Country
US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 20: World Historic Review for Other Therapies by Geographic Region/Country
US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 21: World 14-Year Perspective for Other Therapies by Geographic Region/Country
Percentage Breakdown of Dollar Sales for US, Canada, Europe, and Rest of World Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES
A.Market Analysis
A Surging US Prostate Cancer Therapeutics Market
Table 22: Cancer Incidence and Mortality (in Men) in the US by Type: 2018E (includes corresponding Graph/Chart)
Prostate Cancer Stats: Opportunity Indicator
Table 23: Prostate Cancer Incidence and Mortality in the US by Select Leading States (2018E): No. of New Cancer Cases and No. of Deaths from Prostate Cancer (includes corresponding Graph/Chart)
Table 24: Prostate Cancer Incidence in the US by Age Group: 2017 (includes corresponding Graph/Chart)
Table 25: Probability of Development of Prostate Cancer (in Men) by Age Group in the US, 2012-2014 (includes corresponding Graph/Chart)
Hormone Therapy Dominates Prostate Cancer Drugs Market
Table 26: Sales of Leading Prostate Cancer Drugs in US$ Million in the US: 2017 (includes corresponding Graph/Chart)
High Intensity Focused Ultrasound (HIFU) Approved for Ablation of Prostate Tissue
Drug Approvals and Clinical Studies
Product Launches
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 27: The US Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 28: The US Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 29: The US 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

2. CANADA
A.Market Analysis
Prostate Cancer Stats: Opportunity Indicators
Table 30: New Cancer Cases for Male in Canada by Type (2017): Breakdown of New Cancer Cases Diagnosed for Prostate, Colorectal, Lung & Bronchus, Bladder, Non-Hodgkin Lymphoma, and Others (includes corresponding Graph/Chart)
Table 31: Prostate Cancer Incidence and Mortality in Canada by Leading Province: 2017 (includes corresponding Graph/Chart)
Table 32: Prostate Cancer Incidence and Mortality in Canada by Age Group: 2017 (includes corresponding Graph/Chart)
Clinical Trial
Product Launches
Strategic Corporate Developments
B.Market Analytics
Table 33: Canadian Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 34: Canadian Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 35: Canadian 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

3. EUROPE
A.Market Analysis
Awareness Drives European Prostate Cancer Therapeutics Market
Table 36: Cancer Mortality in the European Union: Percentage Breakdown of Number of Deaths by Cancer Type in 2017 (includes corresponding Graph/Chart)
HIFU Technology Gaining Momentum in Europe
B.Market Analytics
Table 37: European Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region/Country
France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 38: European Historic Review for Prostate Cancer Therapeutics by Geographic Region/Country
France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 39: European 14-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country
Percentage Breakdown of Dollar Sales for France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)
Table 40: European Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 41: European Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 42: European 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)
3a. FRANCE
A.Market Analysis
Sanofi S.A.
A Key France-based Player
B.Market Analytics
Table 43: French Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 44: French Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 45: French 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)
3b. GERMANY
A.Market Analysis
Product Launch
Select Key Player
B.Market Analytics
Table 46: German Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 47: German Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 48: German 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)
3c. ITALY
Market Analysis
Table 49: Italian Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 50: Italian Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 51: Italian 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)
3d. THE UNITED KINGDOM
A.Market Analysis
Table 52: Cancer Incidence and Mortality in the UK by Type: 2015 (includes corresponding Graph/Chart)
Prostate Cancer Research in UK
An Insight
Need for Filling up Gaps in Provision of Care
Dearth of Clinical Researchers
Select Key Players
B.Market Analytics
Table 53: The UK Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 54: The UK Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 55: The UK 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)
3e. SPAIN
Market Analysis
Table 56: Spanish Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 57: Spanish Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 58: Spanish 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)
3f. REST OF EUROPE
A.Market Analysis
Clinical Studies
Product Launch
Strategic Corporate Development
Select Key Players
B.Market Analytics
Table 59: Rest of European Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 60: Rest of European Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 61: Rest of European 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

4. REST OF WORLD
A.Market Analysis
Minimally Invasive Devices to Gain Share in Emerging Markets
Cancer Market in Asia
Australia
India
Table 62: New Incidence Rate of Prostate Cancer (Rate per Million Population) in Asia-Pacific and Latin America for 2012
Table 63: 5-Year Net Survival Rates (%) for Prostate Cancer among Adults 15 Years of Age and Older (2005-2009) in Select Asian and Latin American Countries (includes corresponding Graph/Chart)
Clinical Trials
Select Key Players
B.Market Analytics
Table 64: Rest of World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 65: Rest of World Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 66: Rest of World 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2018 and 2022 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

  • Total Companies Profiled: 76 (including Divisions/Subsidiaries 84)
    • The United States (47)
    • Canada (6)
  • Japan (4)
  • Europe (23)
    • France (5)
    • Germany (3)
    • The United Kingdom (5)
    • Rest of Europe (10)
  • Asia-Pacific (Excluding Japan) (4)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie, Inc. (USA)
  • Allergan plc (Ireland)
  • Amgen, Inc. (USA)
  • Astellas Pharma, Inc. (Japan)
  • AstraZeneca Plc. (UK)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (USA)
  • Debiopharm Group (Switzerland)
  • Dendreon Pharmaceuticals LLC (USA)
  • Endo Pharmaceuticals Inc. (USA)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Genentech Inc. (USA)
  • GlaxoSmithKline Plc. (UK)
  • Janssen Biotech, Inc. (USA)
  • Myovant Sciences Ltd. (UK)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (USA)
  • Progenics Pharmaceuticals, Inc. (USA)
  • Sanofi S.A. (France)
  • Spectrum Pharmaceuticals, Inc. (USA)
  • Takeda Pharmaceutical Company Limited (Japan)
  • TOLMAR Pharmaceuticals, Inc. (USA)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll